PBYI

+ Watchlist + Portfolio

Puma Biotechnology Inc

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $9.49
52-Week Range: $4.30 – $9.51
Market Cap: $470.26M
P/E (TTM): 17.86
EPS (TTM): 0.51
Dividend Yield: —

Advanced Metrics

Price/Book: 3.36
PEG Ratio: —
Return on Equity: 21.97%
Return on Assets: 9.81%
Gross Margin: 74.83%
Operating Margin: 13.42%
Profit Margin: 11.55%
Current Ratio: 2.91
Debt/Equity: 0.03
Total Debt: $4.82M
Free Cash Flow: $32.47M
Revenue Growth: 7.80%
Earnings Growth: 35.80%
Enterprise Value: $400.79M

PBYI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$228.03M	$235.64M	$230.47M	$228.37M
Cost of Revenue	$55.09M	$62.68M	$64.40M	$58.16M
Gross Profit	$172.94M	$172.96M	$166.06M	$170.21M
Research & Development	$52.24M	$50.38M	$54.94M	$62.07M
Selling, General & Admin	$89.98M	$89.93M	$80.68M	$71.21M
Operating Expenses	$142.22M	$140.31M	$135.10M	$132.91M
Operating Income	$30.72M	$32.64M	$30.97M	$37.30M
EBITDA	$21.89M	$47.52M	$48.08M	$53.34M
Pretax Income	$457.00K	$22.67M	$24.10M	$35.78M
Income Tax	$455.00K	$1.08M	-$6.18M	$4.67M
Net Income	$2.00K	$21.59M	$30.28M	$31.11M
Diluted EPS	0.00	0.45	0.62	0.61
Diluted Shares	44.93M	47.55M	49.10M	50.65M

PBYI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$76.20M	$84.58M	$69.22M	$29.64M
Receivables	$42.27M	$47.84M	$32.01M	$53.65M
Inventory	$4.53M	$7.08M	$8.72M	$5.51M
Current Assets	$134.28M	$156.19M	$147.66M	$162.69M
Total Assets	$222.06M	$230.53M	$213.33M	$216.30M
Current Liabilities	$77.48M	$99.38M	$96.11M	$81.25M
Long-Term Debt	$98.31M	$65.66M	$21.72M	—
Total Debt	$114.28M	$111.49M	$74.08M	$28.55M
Total Liabilities	$200.45M	$177.09M	$121.21M	$85.96M
Retained Earnings	-$1.37B	-$1.35B	-$1.31B	-$1.28B
Shareholders' Equity	$21.61M	$53.44M	$92.13M	$130.34M
Working Capital	$56.80M	$56.80M	$51.55M	$81.43M
Net Debt	$22.11M	$15.07M	—	—

PBYI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$15.83M	$27.01M	$38.92M	$41.80M
Capital Expenditure	-$7.00M	-$12.64M	-$56.00K	-$71.00K
Free Cash Flow	-$22.83M	$14.37M	$38.86M	$41.73M
Depreciation & Amortisation	$9.84M	$11.52M	$11.52M	$10.94M
Stock-Based Compensation	$11.83M	$10.25M	$8.24M	$6.94M
Investing Cash Flow	$7.10M	-$19.13M	-$20.44M	-$36.19M
Financing Cash Flow	$12.22M	$0.00	-$33.85M	-$45.20M
Net Change in Cash	$3.50M	$7.88M	-$15.37M	-$39.58M

PBYI Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$52.44M	$54.48M	$75.45M	$44.81M	$56.50M
Cost of Revenue	$12.30M	$12.17M	$23.13M	$10.42M	$12.47M
Gross Profit	$40.13M	$42.30M	$52.33M	$34.39M	$44.03M
Research & Development	$15.45M	$15.91M	$16.84M	$19.80M	$18.89M
Selling, General & Admin	$18.41M	$17.03M	$18.38M	$18.42M	$17.55M
Operating Expenses	$33.50M	$32.73M	$35.22M	$38.22M	$36.44M
Operating Income	$6.64M	$9.57M	$17.11M	-$3.83M	$7.58M
EBITDA	$10.77M	$13.45M	$20.88M	-$112.00K	$10.94M
Pretax Income	$6.17M	$9.24M	$17.11M	-$3.43M	$8.24M
Income Tax	$310.00K	$399.00K	$3.67M	$326.00K	$56.00K
Net Income	$5.86M	$8.84M	$13.44M	-$3.75M	$8.19M
Diluted EPS	0.12	0.17	0.26	-0.07	0.16
Diluted Shares	50.14M	50.93M	51.52M	50.85M	52.60M

PBYI Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$54.66M	$53.52M	$29.64M	$36.19M	$36.54M
Receivables	$25.91M	$33.56M	$53.65M	$26.33M	$34.06M
Inventory	$8.59M	$9.48M	$5.51M	$8.69M	$13.32M
Current Assets	$136.58M	$143.58M	$162.69M	$142.26M	$145.07M
Total Assets	$194.92M	$202.86M	$216.30M	$192.70M	$192.74M
Current Liabilities	$79.10M	$82.73M	$81.25M	$59.74M	$49.83M
Long-Term Debt	$10.87M	—	—	—	—
Total Debt	$49.23M	$41.05M	$28.55M	$15.95M	$4.82M
Total Liabilities	$90.20M	$87.59M	$85.96M	$64.28M	$54.19M
Retained Earnings	-$1.31B	-$1.30B	-$1.28B	-$1.29B	-$1.28B
Shareholders' Equity	$104.72M	$115.27M	$130.34M	$128.42M	$138.54M
Working Capital	$57.48M	$60.85M	$81.43M	$82.52M	$95.25M

PBYI Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$14.08M	$9.69M	$14.42M	$15.42M	$1.62M
Capital Expenditure	-$20.00K	-$26.00K	—	—	—
Free Cash Flow	$14.06M	$9.66M	$14.46M	$15.42M	$1.62M
Depreciation & Amortisation	$2.76M	$2.72M	$2.66M	$2.58M	$2.52M
Stock-Based Compensation	$1.63M	$1.67M	$1.62M	$1.90M	$1.95M
Investing Cash Flow	-$11.25M	$506.00K	-$26.98M	$2.47M	$7.97M
Financing Cash Flow	-$11.20M	-$11.33M	-$11.33M	-$11.33M	-$11.34M
Net Change in Cash	-$8.37M	-$1.14M	-$23.89M	$6.56M	-$1.75M

Market Snapshot

About

Puma Biotechnology is a biopharmaceutical company focused on the development and commercialization of innovative products to enhance cancer care. The company markets NERLYNX (neratinib), an oral kinase inhibitor approved for the extended adjuvant treatment of early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. Puma also has a pipeline of drug candidates in clinical development for various oncology indications. The company was founded in 2010 and is headquartered in Los Angeles, California.